Contact us
menu

The Impact of Aptar Digital Health respiratory disease management platform on indices of asthma control

At the ERS Congress 2026, Aptar Digital Health presented findings from a 6-month prospective study of its respiratory disease management platform, conducted at Guy’s and St Thomas’ NHS Foundation Trust in London. Ninety adults with uncontrolled moderate-to-severe asthma were included in the analysis. While continuing their inhaled controller treatment, participants used the Respi.me app and connected inhaler sensors, and their healthcare professionals monitored them via a dashboard.

Key findings included:

  • Clinically meaningful improvement in asthma control, measured with the ACQ-5 questionnaire
  • Clinically meaningful improvement in asthma-related quality of life, measured with the Mini-AQLQ questionnaire
  • Reduction in airway inflammation, measured with a simple breath test (FeNO)

“Clinically meaningful” means the improvement was larger than the minimum change considered important for patients.

These preliminary findings suggest that digital self-management may complement asthma medication and support better asthma outcomes. As this was a single-arm study without a control group, the results need to be confirmed in future controlled studies.

Back to top
Follow us: subscribe